<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: In <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e>, v-Ki-ras2 Kirsten rat <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog (KRAS) is a predictive biomarker for anti-epidermal growth factor receptor (EGFR) treatment and V-raf murine <z:hpo ids='HP_0100242'>sarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog B1 (BRAF) is a prognostic biomarker </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to determine the impact of KRAS and BRAF mutation as determined from <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> specimens on overall survival (OS) in patients following colorectal liver metastasectomy </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">Liver metastases</z:e> specimens (n = 292) obtained from patients after liver metastasectomy were used to determine the KRAS/BRAF genotype </plain></SENT>
<SENT sid="3" pm="."><plain>Associations between clinicopathological parameters and KRAS/BRAF genotype were identified by univariate and multivariate analyses using the Cox proportional hazards model </plain></SENT>
<SENT sid="4" pm="."><plain>The impact of KRAS/BRAF genotype on survival was analyzed using the Kaplan-Meier method </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The 5-year survival rate of the cohort was 55.8% </plain></SENT>
<SENT sid="6" pm="."><plain>The KRAS and BRAF mutation rates were 38.0 and 2.1%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>BRAF genotype, but not KRAS, was found to be an independent prognostic biomarker (HR = 5.181, P = 0.002) after adjustment for other significant confounding clinicopathological variates: Number of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (HR = 1.983, P = 0.009), concomitant extrahepatic disease (HR = 1.858, P = 0.014), and surgical margin (HR = 3.241, P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>BRAF genotype was an independent prognostic biomarker in patients with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> only after metastasectomy (HR = 6.245, P &lt; 0.003) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: BRAF mutation is an independent prognostic biomarker for colorectal liver metastasectomy </plain></SENT>
</text></document>